The current status, challenges, and future developments of new tuberculosis vaccines

Flow cytometry: An efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis

(2018) Liwei He et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine

(2018) Scott G Hansen et al.   NATURE MEDICINE

Tuberculosis vaccines: Opportunities and challenges

(2018) Bingdong Zhu et al.   RESPIROLOGY

Novel approaches to tuberculosis vaccine development

(2017) Stefan H.E. Kaufmann et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

(2017) Maria Norrby et al.   VACCINE

Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus

(2017) Hiroki Ui et al.   VACCINE

Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial

(2017) Surendra K. Sharma et al.   Scientific Reports

Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis

(2017) Chen-Yi Huang et al.   Human Vaccines & Immunotherapeutics

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

(2017) Anne Wajja et al.   PLoS Neglected Tropical Diseases

Immunogenicity and Protective Efficacy of a Fusion Protein Tuberculosis Vaccine Combining Five Esx Family Proteins

(2017) Zhi-hao Xiang et al.   Frontiers in Cellular and Infection Microbiology

The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing

(2017) Natalie E. Nieuwenhuizen et al.   Frontiers in Immunology

Memory of Natural Killer Cells: A New Chance against Mycobacterium tuberculosis?

(2017) José Alberto Choreño Parra et al.   Frontiers in Immunology

Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity

(2017) Ulrich E. Schaible et al.   Frontiers in Immunology

Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases

(2017) Bas C. Mourik et al.   Frontiers in Immunology

IL-17 Production of Neutrophils Enhances Antibacteria Ability but Promotes Arthritis Development During Mycobacterium tuberculosis Infection

(2017) Shengfeng Hu et al.   EBioMedicine

bioA mutant of Mycobacterium tuberculosis shows severe growth defect and imparts protection against tuberculosis in guinea pigs

(2017) Ritika Kar et al.   PLoS One

Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates

(2016) Else Marie Agger   ADVANCED DRUG DELIVERY REVIEWS

Structure, chain conformation, and immunomodulatory activity of the polysaccharide purified from Bacillus Calmette Guerin formulation

(2016) Wei Liu et al.   CARBOHYDRATE POLYMERS

Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa

(2016) André G. Loxton et al.   Clinical and Vaccine Immunology

Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis

(2016) Yan Liang et al.   CURRENT GENE THERAPY

Selective presentation of MVA85A tuberculosis booster vaccine preclinical animal data

(2016) PCL Beverley   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

BCG vaccine fails to prevent the reactivation of latent tuberculosis

(2016) Kirtimaan Syal   MEDICAL HYPOTHESES

Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice

(2016) Yan Liang et al.   Molecular Medicine Reports

Trained immunity: A program of innate immune memory in health and disease

(2016) M. G. Netea et al.   SCIENCE

Mycobacterium tuberculosis infection and vaccine development

(2016) Jiansong Tang et al.   TUBERCULOSIS

Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling

(2016) Shibali Das et al.   TUBERCULOSIS

Antibodies and tuberculosis

(2016) Ashley J. Jacobs et al.   TUBERCULOSIS

Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study

(2016) Paul Gillard et al.   TUBERCULOSIS

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains

(2016) Richard C. Condit et al.   VACCINE

A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice

(2016) Xun Liu et al.   VACCINE

Lipoprotein LpqS deficient M. tuberculosis mutant is attenuated for virulence in vivo and shows protective efficacy better than BCG in guinea pigs

(2016) Suba Sakthi et al.   VACCINE

Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG Δ ureC :: hly Improves Protection against Tuberculosis

(2016) Martin Gengenbacher et al.   mBio

Immunometabolic Pathways in BCG-Induced Trained Immunity

(2016) Rob J.W. Arts et al.   Cell Reports

Endosomal MR1 Trafficking Plays a Key Role in Presentation of Mycobacterium tuberculosis Ligands to MAIT Cells

(2016) Melanie J. Harriff et al.   PLoS Pathogens

Towards new TB vaccines: What are the challenges?

(2016) Hazel M. Dockrell   Pathogens and Disease

Targeting Innate-Like T Cells in Tuberculosis

(2016) Shouxiong Huang   Frontiers in Immunology

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

(2016) Daniel F. Hoft et al.   EBioMedicine

Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis

(2016) Timothy Lahey et al.   PLoS One

Purification and characterization of a glucan from Bacillus Calmette Guerin and the antitumor activity of its sulfated derivative

(2015) Xiongbo Xu et al.   CARBOHYDRATE POLYMERS

Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate

(2015) Susan L. Baldwin et al.   Clinical and Vaccine Immunology

B cells and antibodies in the defense againstMycobacterium tuberculosisinfection

(2015) Jacqueline M. Achkar et al.   IMMUNOLOGICAL REVIEWS

CD226 as a genetic adjuvant to enhance immune efficacy induced by Ag85A DNA vaccination

(2015) Yan Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review

(2015) Rufaro Kashangura et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

NOD-2 and TLR-4 Signaling Reinforces the Efficacy of Dendritic Cells and Reduces the Dose of TB Drugs against Mycobacterium tuberculosis

(2015) Nargis Khan et al.   Journal of Innate Immunity

Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection

(2015) Jin-biao Lu et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination

(2015) Nada Daifalla et al.   MICROBES AND INFECTION

Chloroform-Methanol Residue of Coxiella burnetii Markedly Potentiated the Specific Immunoprotection Elicited by a Recombinant Protein Fragment rOmpB-4 Derived from Outer Membrane Protein B of Rickettsia rickettsii in C3H/HeN Mice

(2015) Wenping Gong et al.   PLoS One

The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

(2015) Gavin John Churchyard et al.   VACCINE

Enhanced protection against Rickettsia rickettsii infection in C3H/HeN mice by immunization with a combination of a recombinant adhesin rAdr2 and a protein fragment rOmpB-4 derived from outer membrane protein B

(2015) Wenping Gong et al.   VACCINE

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

(2015) Angelique Kany Kany Luabeya et al.   VACCINE

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

(2015) E. Stylianou et al.   VACCINE

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants

(2015) M. Tameris et al.   VACCINE

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

(2015) Hennie Geldenhuys et al.   VACCINE

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting

(2015) Adam Penn-Nicholson et al.   VACCINE

A high ratio of IC31®adjuvant to antigen is necessary for H4 TB vaccine immunomodulation

(2015) Sepideh Aboutorabian et al.   Human Vaccines & Immunotherapeutics

Rickettsia rickettsiiouter membrane protein YbgF induces protective immunity in C3H/HeN mice

(2015) Wenping Gong et al.   Human Vaccines & Immunotherapeutics

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial

(2015) François Spertini et al.   Lancet Respiratory Medicine

AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates

(2015) Mangalakumari Jeyanathan et al.   PLoS One

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

(2015) Sharon Sheehan et al.   PLoS One

The ID93 Tuberculosis Vaccine Candidate Does Not Induce Sensitivity to Purified Protein Derivative

(2014) Susan L. Baldwin et al.   Clinical and Vaccine Immunology

521 VPM1002 – a recombinant BCG with favourable preclinical toxicity and immunogenicity for potential improvement of BCG immunotherapy for non-muscle invasive bladder cancer

(2014) C.A. Rentsch et al.   EUROPEAN UROLOGY SUPPLEMENTS

Neutrophils from pulmonary tuberculosis patients show augmented levels of chemokines MIP-1α, IL-8 and MCP-1 which further increase upon in vitro infection with mycobacterial strains

(2014) J. Nancy Hilda et al.   HUMAN IMMUNOLOGY

Beyond macrophages: the diversity of mononuclear cells in tuberculosis

(2014) Smita Srivastava et al.   IMMUNOLOGICAL REVIEWS

Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy againstMycobacterium tuberculosisin mice

(2014) Ying Xu et al.   IMMUNOLOGY

Simultaneous Inhibition of T Helper 2 and T Regulatory Cell Differentiation by Small Molecules Enhances Bacillus Calmette-Guerin Vaccine Efficacy against Tuberculosis

(2014) Debapriya Bhattacharya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Aerosol Vaccination with AERAS-402 Elicits Robust Cellular Immune Responses in the Lungs of Rhesus Macaques but Fails To Protect against High-DoseMycobacterium tuberculosisChallenge

(2014) Patricia A. Darrah et al.   JOURNAL OF IMMUNOLOGY

Immunogenicity of a Recombinant Mycobacterium smegmatis Vaccine Expressing the Fusion Protein CMX in Cattle from Goiás State, Brazil

(2014) Duanne ALVES DA SILVA et al.   JOURNAL OF VETERINARY MEDICAL SCIENCE

Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL/6 mice

(2014) Enzhuo Yang et al.   MICROBIAL PATHOGENESIS

Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection

(2014) Andre S. Nell et al.   PLoS One

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses

(2014) Michele Tameris et al.   PLoS One

Identification of Novel Surface-Exposed Proteins of Rickettsia rickettsii by Affinity Purification and Proteomics

(2014) Wenping Gong et al.   PLoS One

Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial

(2014) Klaus Reither et al.   PLoS One

TB vaccine development: where are we and why is it so difficult?

(2014) M. E. M. Wilkie et al.   THORAX

Surface protein Adr2 of Rickettsia rickettsii induced protective immunity against Rocky Mountain spotted fever in C3H/HeN mice

(2014) Wenping Gong et al.   VACCINE

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

(2014) Jaap T. van Dissel et al.   VACCINE

Dietary Pyridoxine Controls Efficacy of Vitamin B6-Auxotrophic Tuberculosis Vaccine Bacillus Calmette-Guerin  ureC::hly  pdx1 in Mice

(2014) M. Gengenbacher et al.   mBio

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis

(2014) Teresa Prezzemolo et al.   Frontiers in Immunology

Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine Development

(2013) Jacqueline M. Achkar et al.   Cell Host & Microbe

Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques

(2013) A. D. White et al.   Clinical and Vaccine Immunology

Recent developments in tuberculosis vaccines

(2013) Dessislava Marinova et al.   Expert Review of Vaccines

A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults

(2013) Jaime Montoya et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6

(2013) Yi-Hao Deng et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

(2013) Michele D Tameris et al.   LANCET

Mycobacterium tuberculosis antigen 85B and ESAT-6 expressed as a recombinant fusion protein in Mycobacterium smegmatis elicits cell-mediated immune response in a murine vaccination model

(2013) Anthony G. Tsolaki et al.   MOLECULAR IMMUNOLOGY

Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans

(2013) Iñaki Comas et al.   NATURE GENETICS

Subunit Vaccine Consisting of Multi-Stage Antigens Has High Protective Efficacy against Mycobacterium tuberculosis Infection in Mice

(2013) Qi Xin et al.   PLoS One

The Tuberculosis Vaccine Candidate Bacillus Calmette-Guérin ΔureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in Mice

(2013) Martin Rao et al.   PLoS One

Secretory Phosphatases Deficient Mutant of Mycobacterium tuberculosis Imparts Protection at the Primary Site of Infection in Guinea Pigs

(2013) Priyanka Chauhan et al.   PLoS One

A Human Type 5 Adenovirus-Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity

(2013) F. Smaill et al.   Science Translational Medicine

Neutrophils in innate and adaptive immunity

(2013) Sébastien Jaillon et al.   Seminars in Immunopathology

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

(2013) Leander Grode et al.   VACCINE

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials

(2013) Ainhoa Arbues et al.   VACCINE

The current state of tuberculosis vaccines

(2013) David A Hokey et al.   Human Vaccines & Immunotherapeutics

Current trends in separation of plasmid DNA vaccines: A review

(2012) Ashraf Ghanem et al.   ANALYTICA CHIMICA ACTA

Goats Primed with Mycobacterium bovis BCG and Boosted with a Recombinant Adenovirus Expressing Ag85A Show Enhanced Protection against Tuberculosis

(2012) Bernat Pérez de Val et al.   Clinical and Vaccine Immunology

Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected withMycobacterium tuberculosis

(2012) Yan Liang et al.   FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY

The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

(2012) S. L. Baldwin et al.   JOURNAL OF IMMUNOLOGY

IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease

(2012) Javier O. Jurado et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines

(2012) Satria A. Prabowo et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection

(2012) Gareth Betts et al.   PLoS One

Novel Recombinant BCG Coexpressing Ag85B, ESAT-6 and Rv2608 Elicits Significantly Enhanced Cellular Immune and Antibody Responses in C57BL/6 Mice

(2012) Y. Lu et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity

(2012) Daniel F. Hoft et al.   VACCINE

Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model

(2012) Ankan Gupta et al.   VACCINE

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery

(2012) Joel Meyer et al.   VACCINE

Improved Cellular Immune Response Elicited by a Ubiquitin-Fused DNA Vaccine Against Mycobacterium tuberculosis

(2011) Qingmin Wang et al.   DNA AND CELL BIOLOGY

Outbreaks of Mycobacterium Tuberculosis MDR Strains Induce High IL-17 T-Cell Response in Patients With MDR Tuberculosis That Is Closely Associated With High Antigen Load

(2011) Juan I. Basile et al.   JOURNAL OF INFECTIOUS DISEASES

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis

(2011) Kari A Sweeney et al.   NATURE MEDICINE

A multistage tuberculosis vaccine that confers efficient protection before and after exposure

(2011) Claus Aagaard et al.   NATURE MEDICINE

Interferon Gamma Activated Macrophages Kill Mycobacteria by Nitric Oxide Induced Apoptosis

(2011) Susanne Herbst et al.   PLoS One

Mycobacterium vaccae as Adjuvant Therapy to Anti-Tuberculosis Chemotherapy in Never-Treated Tuberculosis Patients: A Meta-Analysis

(2011) Xiao-Yan Yang et al.   PLoS One

Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens

(2011) Stephen T. Reece et al.   VACCINE

Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

(2010) Charles F von Reyn et al.   AIDS

CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition

(2010) D. L. Barber et al.   JOURNAL OF IMMUNOLOGY

Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-α induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice

(2010) Hongbo Shen et al.   MICROBIOLOGY AND IMMUNOLOGY

Recombinant Mycobacterium smegmatis Expressing an ESAT6-CFP10 Fusion Protein Induces Anti-Mycobacterial Immune Responses and Protects Against Mycobacterium tuberculosis Challenge in Mice

(2010) H. Zhang et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

(2010) S. Bertholet et al.   Science Translational Medicine

Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

(2010) Jaap T. van Dissel et al.   VACCINE

Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, inMycobacterium tuberculosis–infected Individuals

(2009) Clare R. Sander et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65(Hsp65) with human interleukin-2 againstMycobacterium tuberculosisin BALB/c mice 

(2009) LI-MEI WANG et al.   APMIS

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines

(2009) Consuelo Ortega et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Potential role for ESAT6 in dissemination ofM. tuberculosisvia human lung epithelial cells

(2009) Arvind G. Kinhikar et al.   MOLECULAR MICROBIOLOGY

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin

(2009) David J. M. Lewis et al.   PLoS One

Polyphasic Taxonomic Analysis Establishes Mycobacterium indicus pranii as a Distinct Species

(2009) Vikram Saini et al.   PLoS One

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis

(2009) Ronggai Sun et al.   VACCINE

Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates

(2009) Michelle H. Larsen et al.   VACCINE

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®

(2009) C. Vilaplana et al.   VACCINE

Induction of a Specific Strong Polyantigenic Cellular Immune Response after Short-Term Chemotherapy Controls Bacillary Reactivation in Murine and Guinea Pig Experimental Models of Tuberculosis

(2008) E. Guirado et al.   Clinical and Vaccine Immunology

Effect of recombinant Rv1009 protein on promoting the growth ofMycobacterium tuberculosis

(2008) X. Wu et al.   JOURNAL OF APPLIED MICROBIOLOGY

Efficacy of Recombinant Bacille Calmette‐Guérin Vaccine Secreting Interleukin‐15/Antigen 85B Fusion Protein in Providing Protection againstMycobacterium tuberculosis

(2008) Ce Tang et al.   JOURNAL OF INFECTIOUS DISEASES

A New Recombinant Bacille Calmette‐Guérin Vaccine Safely Induces Significantly Enhanced Tuberculosis‐Specific Immunity in Human Volunteers

(2008) Daniel F. Hoft et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa

(2008) Tony Hawkridge et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of Attenuation of Treg during BCG Immunization on Anti-Mycobacterial Th1 Responses and Protection against Mycobacterium tuberculosis

(2008) Barbara Jaron et al.   PLoS One

The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin

(2008) Yan Liang et al.   VACCINE

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis

(2008) K. Katoch et al.   VACCINE